Eli Lilly and Company (LLY) is considered one of the best forever stocks by hedge funds, with Goldman Sachs raising its price target to $1,145 on December 15. The company recently provided updated data on its breast cancer treatment, Inluriyo, showing a 38% reduction in risk of progression or death and a median progression-free survival of 11 months.

The updated data for Inluriyo as a monotherapy has been deemed clinically meaningful by Eli Lilly, following FDA approval. In response to the need for lower prices for GLP-1 medications, the company announced plans to offer reduced prices for single-dose vials of Zepbound (tirzepatide), with discounts of $50 to $100 depending on dosage.

Eli Lilly and Company is a global pharmaceutical company focused on diabetes and animal health products. While LLY holds investment potential, some believe certain AI stocks offer greater upside potential with less downside risk.

For more information on top materials stocks and best organic food and farming stocks, visit Insider Monkey.

Read more at Yahoo Finance: Eli Lilly and Company (LLY) Announces Updated Meaningful Data on Breast Cancer Treatment